Trial Profile
Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2022
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 01 Sep 2022 Results published in the Cancer Chemotherapy and Pharmacology
- 31 May 2020 According to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology, analysis of PK data is ongoing and will be reported.
- 31 May 2020 Results from this study, were presented at the 56th Annual Meeting of the American Society of Clinical Oncology.